129473-55-8Relevant articles and documents
A study of the various factors that affect the properties of molecularly imprinted polymers
Yasuyama, Takuro,Matsunaga, Hirofumi,Ando, Shin,Ishizuka, Tadao
, p. 546 - 550 (2013)
We evaluated the adsorbability and selectivity of (S)-valine anilide imprinted molecularly imprinted polymer (MIP) using a batch procedure that is both independent and precise. This study revealed important information about the relationship between the performance of MIPs and experimental factors such as the components of MIP synthesis and a reaction solvent. Herein, we also describe the problems associated with the preparation of a non-imprinted polymer, which is often used to evaluate the effect of a template molecule, and we propose a new type of reference polymer, blank polymer .
Amino Acid-Functionalized Metal-Organic Frameworks for Asymmetric Base–Metal Catalysis
Newar, Rajashree,Akhtar, Naved,Antil, Neha,Kumar, Ajay,Shukla, Sakshi,Begum, Wahida,Manna, Kuntal
, p. 10964 - 10970 (2021/03/29)
We report a strategy to develop heterogeneous single-site enantioselective catalysts based on naturally occurring amino acids and earth-abundant metals for eco-friendly asymmetric catalysis. The grafting of amino acids within the pores of a metal-organic framework (MOF), followed by post-synthetic metalation with iron precursor, affords highly active and enantioselective (>99 % ee for 10 examples) catalysts for hydrosilylation and hydroboration of carbonyl compounds. Impressively, the MOF-Fe catalyst displayed high turnover numbers of up to 10 000 and was recycled and reused more than 15 times without diminishing the enantioselectivity. MOF-Fe displayed much higher activity and enantioselectivity than its homogeneous control catalyst, likely due to the formation of robust single-site catalyst in the MOF through site-isolation.
Linker, Antibody-Drug Conjugate Including Same and Use Thereof
-
, (2021/08/27)
Provided are a linker represented by Formula I or I′, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.
Synthetic process of chiral N-aromatic amino acid amide
-
Paragraph 0010; 0014, (2016/10/17)
Chiral N-aromatic amino acid amide is a core structure fragment of drugs and an intermediate of the drugs. Only if the chiral structure of the product is not required by special raw materials such aryl halide activated by functional groups of nitryl and t